Search
Levoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalIn vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. … However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Categories: Sex Hormones and Modulators of the Genital SystemClozapine
go.drugbank.com/drugs/DB00363ApprovedInvestigational[A256708] Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical … [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL.
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDoxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T559] It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. … [L5971] However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.[L5974]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: DOXEPIN DURA T 50MG, DOXEPIN DURA T 100MGOmega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalOmega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. … On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids.
Mixtures: Se-Tan DHA, Se-Tan DHALamivudine
go.drugbank.com/drugs/DB00709ApprovedInvestigationalA reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. … It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Mixtures: LAMIHOPE-T (LAMIVUDINE 300MG AND TENOFOVIR DISOPROXIL FUMARATE 300MG FILM-COATED TABLETS), TENOLAM-ECategories: Antivirals used in combination for the treatment of HIV infectionsCannabidiol
go.drugbank.com/drugs/DB09061ApprovedInvestigationalOn June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: leafPro CBDmed Oil T-FS QD 5%, leafPro CBDmed Oil T-FS QD 20%Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. … [A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Categories: Agents to Treat Airway DiseaseProducts: BROMURO DE TIOTROPIO 18 µG CÁPSULA, TIOSYNT BROMURO DE TIOTROPIO 18 MCG /POLVO PARA INHALACIONRotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalLike other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. … In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome